Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis. [PDF]
Zhang Y +6 more
europepmc +1 more source
Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product
Richard K. Burdick +2 more
openalex +1 more source
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]
Beinfeld MT +5 more
europepmc +1 more source
Formulation of Recombinant Therapeutic Proteins: Technological Innovation, Regulations, and Evolution Towards Buffer-Free Formulations. [PDF]
Bas TG.
europepmc +1 more source
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects [PDF]
core +1 more source
NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars. [PDF]
Baldisseri D +9 more
europepmc +1 more source
Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]
Matsumoto M +11 more
europepmc +1 more source
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
Abdelaziz A +3 more
europepmc +1 more source
Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study. [PDF]
Au LSJ, Luk MY, Lee VHF, Yuen KK.
europepmc +1 more source

